BROWSE

ITEM VIEW & DOWNLOAD

Enhanced antibody responses in fully vaccinated individuals against pan-SARS-CoV-2 variants following Omicron breakthrough infection

DC Field Value Language
dc.contributor.authorJeong, Hye Won-
dc.contributor.authorSe-Mi Kim-
dc.contributor.authorMin Kyung Jung-
dc.contributor.authorNoh, Ji Yun-
dc.contributor.authorJi-Seung Yoo-
dc.contributor.authorKim, Eun-Ha-
dc.contributor.authorYoung-Il Kim-
dc.contributor.authorYu, Kwangmin-
dc.contributor.authorSeung-Gyu Jang-
dc.contributor.authorGil, Juryeon-
dc.contributor.authorMark Anthony Casel-
dc.contributor.authorRollon Rare-
dc.contributor.authorChoi, Jeong Ho-
dc.contributor.authorKim, Hee-Sung-
dc.contributor.authorKim, Jun Hyoung-
dc.contributor.authorUm, Jihye-
dc.contributor.authorChaeyoon Kim-
dc.contributor.authorKim, Yeonjae-
dc.contributor.authorChin, Bum Sik-
dc.contributor.authorJung, Sungmin-
dc.contributor.authorChoi, Jun Yong-
dc.contributor.authorSong, Kyoung-Ho-
dc.contributor.authorKim, Yong-Dae-
dc.contributor.authorPark, Jun-Sun-
dc.contributor.authorSong, Joon Young-
dc.contributor.authorEui-Cheol Shin-
dc.contributor.authorYoung Ki Choi-
dc.date.accessioned2023-01-26T02:43:08Z-
dc.date.available2023-01-26T02:43:08Z-
dc.date.created2022-10-29-
dc.date.issued2022-10-
dc.identifier.issn2666-3791-
dc.identifier.urihttps://pr.ibs.re.kr/handle/8788114/12700-
dc.description.abstract© 2022 The Author(s)Omicron has become the globally dominant severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variant, creating additional challenges due to its ability to evade neutralization. Here, we report that neutralizing antibodies against Omicron variants are undetected following COVID-19 infection with ancestral or past SARS-CoV-2 variant viruses or after two-dose mRNA vaccination. Compared with two-dose vaccination, a three-dose vaccination course induces broad neutralizing antibody responses with improved durability against different SARS-CoV-2 variants, although neutralizing antibody titers against Omicron remain low. Intriguingly, among individuals with three-dose vaccination, Omicron breakthrough infection substantially augments serum neutralizing activity against a broad spectrum of SARS-CoV-2 variants, including Omicron variants BA.1, BA.2, and BA.5. Additionally, after Omicron breakthrough infection, memory T cells respond to the spike proteins of both ancestral and Omicron SARS-CoV-2 by producing cytokines with polyfunctionality. These results suggest that Omicron breakthrough infection following three-dose mRNA vaccination induces pan-SARS-CoV-2 immunity that may protect against emerging SARS-CoV-2 variants of concern.-
dc.language영어-
dc.publisherCell Press-
dc.titleEnhanced antibody responses in fully vaccinated individuals against pan-SARS-CoV-2 variants following Omicron breakthrough infection-
dc.typeArticle-
dc.type.rimsART-
dc.identifier.wosid000917310900002-
dc.identifier.scopusid2-s2.0-85139299618-
dc.identifier.rimsid79011-
dc.contributor.affiliatedAuthorSe-Mi Kim-
dc.contributor.affiliatedAuthorMin Kyung Jung-
dc.contributor.affiliatedAuthorJi-Seung Yoo-
dc.contributor.affiliatedAuthorYoung-Il Kim-
dc.contributor.affiliatedAuthorSeung-Gyu Jang-
dc.contributor.affiliatedAuthorMark Anthony Casel-
dc.contributor.affiliatedAuthorRollon Rare-
dc.contributor.affiliatedAuthorChaeyoon Kim-
dc.contributor.affiliatedAuthorEui-Cheol Shin-
dc.contributor.affiliatedAuthorYoung Ki Choi-
dc.identifier.doi10.1016/j.xcrm.2022.100764-
dc.identifier.bibliographicCitationCell Reports Medicine, v.3, no.10-
dc.relation.isPartOfCell Reports Medicine-
dc.citation.titleCell Reports Medicine-
dc.citation.volume3-
dc.citation.number10-
dc.type.docTypeArticle-
dc.description.journalClass1-
dc.description.journalClass1-
dc.description.isOpenAccessN-
dc.description.journalRegisteredClassscie-
dc.description.journalRegisteredClassscopus-
dc.relation.journalResearchAreaCell Biology-
dc.relation.journalResearchAreaResearch & Experimental Medicine-
dc.relation.journalWebOfScienceCategoryCell Biology-
dc.relation.journalWebOfScienceCategoryMedicine, Research & Experimental-
dc.subject.keywordPlusNEUTRALIZING ANTIBODIES-
dc.subject.keywordPlusSARS-COV-2-
dc.subject.keywordPlusIMMUNITY-
dc.subject.keywordPlusMATURATION-
dc.subject.keywordPlusBREADTH-
dc.subject.keywordPlusPOTENCY-
dc.subject.keywordAuthorrecovered patient-
dc.subject.keywordAuthorSARS-CoV-2-
dc.subject.keywordAuthorT cell immune response-
dc.subject.keywordAuthorvariants of concern-
dc.subject.keywordAuthorancestral-
dc.subject.keywordAuthorbreakthrough infection-
dc.subject.keywordAuthorcross-neutralization-
dc.subject.keywordAuthorD614G-
dc.subject.keywordAuthormRNA vaccine-
dc.subject.keywordAuthorOmicron BA.1-
dc.subject.keywordAuthorOmicron BA.2-
Appears in Collections:
Korea Virus Research Institute(한국바이러스기초연구소) > Center for Study of Emerging and Re-emerging Viruses(신변종 바이러스 연구센터) > 1. Journal Papers (저널논문)
Korea Virus Research Institute(한국바이러스기초연구소) > Center for Viral Immunology(바이러스 면역 연구센터) > 1. Journal Papers (저널논문)
Korea Virus Research Institute(한국바이러스기초연구소) > 1. Journal Papers (저널논문)
Files in This Item:
There are no files associated with this item.

qrcode

  • facebook

    twitter

  • Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.
해당 아이템을 이메일로 공유하기 원하시면 인증을 거치시기 바랍니다.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse